Market Overview:

The global oligonucleotide synthesis market reached a value of US$ 2.4 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 4.8 Billion by 2027, exhibiting a CAGR of 12.71% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Oligonucleotide synthesis is a chemical process wherein short fragments of nucleic acids are linked to each other for forming desired sequenced products. It can be customized by researchers according to the application and their requirements. It is used as primers and probes in recombinant DNA technologies to develop monoclonal antibodies. It is also utilized in biological, medical, forensic, and clinical applications for gene expression, cloning, molecular diagnostics, and genetic disease screening. Moreover, it is gaining traction in therapeutics practices for several drugs on account of the introduction of automated reactor platforms, which provide access to oligonucleotides at reasonable prices.

With the increasing cases of coronavirus disease (COVID-19) and the urgency for a potential treatment, new generations of oligonucleotide drugs, including mRNA and DNA vaccines, are currently under development. Apart from this, the growing incidences of cancer and other chronic illnesses have resulted in the rising demand for novel diagnostics, which is influencing the need for oligonucleotide synthesis to help develop effective therapies and diagnostic techniques. The increasing geriatric population and demand for personalized medicines are also bolstering the market growth. Additionally, with advances in purification and quality control technologies, the overall cost of oligonucleotide techniques can be decreased while substantially increasing quality and yield. This is promoting the application of oligonucleotide synthesis in a range of available modifications. Apart from this, several oligonucleotide-based therapies are in different stages of clinical trials. This is anticipated to propel the demand for oligonucleotide synthesis to treat viral infections, rare genetic disorders, and neuromuscular conditions.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global oligonucleotide synthesis market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, application and end use.

Breakup by Product:

• Synthesized Oligonucleotide Products
• Reagents
• Equipment
• Services
   

Breakup by Application:

• PCR Primers
• PCR Assays and Panels
• Sequencing
• DNA Microarrays
• Fluorescence In-Situ Hybridization (FISH)
• Antisense Oligonucleotides
• Others
   

Breakup by End Use:

• Pharmaceutical and Biotechnology Companies
• Hospital and Diagnostic Laboratories
• Academic Research Institutes
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Biolegio B.V., Bio-Synthesis Inc, Eurofins Genomics, GenScript, Horizon Discovery Ltd, Integrated DNA Technologies Inc (Danaher Corporation), Kaneka Eurogentec S.A. (Kaneka Corporation), LGC Limited, Nitto Denko Avecia Inc (Nitto Denko Corporation) and Thermo Fisher Scientific Inc.

Report Coverage: